PARP1 and neoplasm: Given that defects in HR impair the repair of DNA double-strand breaks caused by chemotherapeutic agents such as cisplatin, and are synthetic lethal to inhibition of PARP19, the tumor’s genomic profile was considered actionable and off-label therapy with the PARP inhibitor olaparib at 800 mg daily was initiated.